Efficacy of nepafenac and flurbiprofen in maintaining intraoperative mydriasis during phacoemusification: a comparative study

Session Details

Session Title: Cataract Surgery Instrumentation/Surgical Devices

Session Date/Time: Sunday 11/09/2016 | 10:30-12:00

Paper Time: 10:42

Venue: Hall C1

First Author: : A.Shrivastava INDIA

Co Author(s): :    S. Mushriff   K. Singh   D. Verma              

Abstract Details

Purpose:

To compare the efficacy of Nepafenac (0.1%) with Flurbiprofen (0.03%) in maintaining intraoperative mydriasis during Phacoemulsification Surgery

Setting:

Tertiary care teaching hospital in central India

Methods:

This single-centre, double-blind randomized clinical study comprised 60 patients, divided into two groups (30 each), scheduled for Phacoemulsification. They were randomized to receive nepafenac (0.1%) in one group & flurbiprofen (0.03%) in the other. Pre-operatively all patients received tropicamide 0.8% and phenylephrine 5% eye drops 4 times, at an interval of 15 minutes. Surgery in all the cases was done by the same ophthalmologist, with intra-operative epinephrine (1:1000) in the irrigating solution under local anaesthesia. Horizontal pupil diameter was measured with caliper, immediately before the surgical incision, at the end of phacoemulsification, and at the end of surgery

Results:

All the patients achieved horizontal pupil diameter ≥ 7mm at the start of surgery. The mean horizontal diameter of pupil at end of surgery was 7.88 ± 0.76 mm in nepafenac group and 7.15 ± 1.00 mm in flurbiprofen group (P- Value =0.003) which was statistically significant. In the nepafenac group, the pupil size at the end of surgery decreased by a mean of 0.55 ± 0.51 mm (range 0-1.5 mm), while in flurbiprofen group the pupil size decreased by a mean of 0.93 ±0.63 mm (range 0 -2mm). This difference was statistically significant (P = 0.016).

Conclusions:

The pre-operative use of nepafenac 0.1% eye drops was more effective in maintaining intraoperative mydriasis as compared to flurbiprofen 0.03% during phacoemusification surgery, thereby reducing intraoperative complications and improving surgical outcome.

Financial Disclosure:

NONE